AN OPEN-LABEL, MULTICENTRE SAFETY STUDY OF VEMURAFENIB IN PATIENTS WITH METASTATIC MELANOMA

被引：0
|
作者：
Blank, C. [1 ]
Del Vecchio, M. [2 ]
Ascierto, P. A. [3 ]
Queirolo, P. [4 ]
Hauschild, A. [5 ]
Arance, A. [6 ]
Brown, M. [7 ]
Mitchell, L. [8 ]
Veronese, L. [8 ]
Larkin, J. [9 ]
机构：
[1] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands
[2] Inst Nazl Tumori, Dept Med Oncol, Milan, Italy
[3] Ist Nazl Tumori Fdn G Pascale, Unit Med Oncol & Innovat Therapy, Naples, Italy
[4] San Martino Hosp, Natl Inst Canc Res, Genoa, Italy
[5] Univ Klinikum Schleswig Holstein, Klin Dermatol Venerol & Allergol, Kiel, Germany
[6] Hosp Clin Barcelona, Barcelona, Spain
[7] Royal Adelaide Hosp, Ctr Canc, Adelaide, SA 5000, Australia
[8] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[9] Royal Marsden Hosp, Dept Med, London SW3 6JJ, England
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：366 / 366
页数：1
相关论文
共 50 条
  • [1] Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
    Larkin, James
    Del Vecchio, Michele
    Ascierto, Paolo A.
    Krajsova, Ivana
    Schachter, Jacob
    Neyns, Bart
    Espinosa, Enrique
    Garbe, Claus
    Sileni, Vanna Chiarion
    Gogas, Helen
    Miller, Wilson H., Jr.
    Mandala, Mario
    Hospers, Geke A. P.
    Arance, Ana
    Queirolo, Paola
    Hauschild, Axel
    Brown, Michael P.
    Mitchell, Lada
    Veronese, Luisa
    Blank, Christian U.
    LANCET ONCOLOGY, 2014, 15 (04): : 436 - 444
  • [2] Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study
    McArthur, G. A.
    Maio, M.
    Arance, A.
    Nathan, P.
    Blank, C.
    Avril, M. -F.
    Garbe, C.
    Hauschild, A.
    Schadendorf, D.
    Hamid, O.
    Fluck, M.
    Thebeau, M.
    Schachter, J.
    Kefford, R.
    Chamberlain, M.
    Makrutzki, M.
    Robson, S.
    Gonzalez, R.
    Margolin, K.
    ANNALS OF ONCOLOGY, 2017, 28 (03) : 634 - 641
  • [3] An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system
    Larkin, James
    Brown, Michael P.
    Arance, Ana M.
    Hauschild, Axel
    Queirolo, Paola
    Del Vecchio, Michele
    Ascierto, Paolo A.
    Krajsova, Ivana
    Schachter, Jacob
    Neyns, Bart
    Garbe, Claus
    Sileni, Vanna Chiarion
    Mandala, Mario
    Gogas, Helen
    Espinosa, Enrique
    Hospers, Geke
    Lorigan, Paul
    Nyakas, Marta
    Guminski, Alex
    Liszkay, Gabriela
    Rutkowski, Piotr
    Miller, Wilson, Jr.
    Donica, Margarita
    Makrutzki, Martina
    Blank, Christian
    EUROPEAN JOURNAL OF CANCER, 2019, 107 : 175 - 185
  • [4] Open-label, multicenter safety study of vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma
    Larkin, James M. G.
    Del Vecchio, Michele
    Ascierto, Paolo Antonio
    Schachter, Jacob
    Garbe, Claus
    Neyns, Bart
    Mandala, Mario
    Lorigan, Paul
    Miller, Wilson H.
    Guminski, Alexander David
    Berking, Carola
    Rutkowski, Piotr
    Queirolo, Paola
    Hauschild, Axel
    Arance, Ana Maria
    Brown, Michael Paul
    Mitchell, Lada
    Veronese, Maria Luisa
    Blank, Christian U.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma.
    Larkin, James M. G.
    Queirolo, Paola
    Arance, Ana M.
    Brown, Michael Paul
    Hauschild, Axel
    Del Vecchio, Michele
    McArthur, Grant A.
    Neyns, Bart
    Becker, Juergen C.
    Hansson, Johan
    Hogg, David
    Antonio Ascierto, Paolo
    Loquai, Carmen
    Espinosa, Enrique
    Garbe, Claus
    Patel, Poulam M.
    Schachter, Jacob
    Mitchell, Lada
    Luisa Veronese, Maria
    Blank, Christian U.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases.
    Dummer, R.
    Rinderknecht, J.
    Goldinger, S. M.
    Wagner, I.
    Mitchell, L.
    Veronese, M. L.
    Nick, S.
    Hilfiker, P.
    Gobbi, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] A single-arm, open-label, US expanded access study of vemurafenib in patients with metastatic melanoma.
    Schuchter, Lynn Mara
    Flaherty, Lawrence E.
    Hamid, Omid
    Linette, Gerald P.
    Hallmeyer, Sigrun
    Gonzalez, Rene
    Cowey, Charles Lance
    Pavlick, Anna C.
    Kudrik, Fred J.
    Lawson, David H.
    Margolin, Kim Allyson
    Ribas, Antoni
    McDermott, David F.
    Khatcheressian, James L.
    Flaherty, Keith T.
    Day, Bann-Mo
    Linke, Rolf Gerhard
    Hainsworth, John D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States
    Flaherty, Lawrence
    Hamid, Omid
    Linette, Gerald
    Schuchter, Lynn
    Hallmeyer, Sigrun
    Gonzalez, Rene
    Cowey, C. Lance
    Pavlick, Anna
    Kudrik, Fred
    Curti, Brendan
    Lawson, David
    Chapman, Paul B.
    Margolin, Kim
    Ribas, Antoni
    McDermott, David
    Flaherty, Keith
    Cranmer, Lee
    Hodi, F. Stephen
    Day, Bann-Mo
    Linke, Rolf
    Hainsworth, John
    CANCER JOURNAL, 2014, 20 (01): : 18 - 24
  • [9] OPEN-LABEL PILOT STUDY OF VEMURAFENIB IN PREVIOUSLY TREATED METASTATIC MELANOMA (MM) PATIENTS (PTS) WITH SYMPTOMATIC BRAIN METASTASES (BM)
    Dummer, R.
    Goldinger, S.
    Turtschi, C.
    Eggmann, N.
    Michielin, O.
    Mitchell, L.
    Veronese, L.
    Hilfiker, P. R.
    Rinderknecht, J. D.
    ANNALS OF ONCOLOGY, 2012, 23 : 366 - 366
  • [10] Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study
    LANCET ONCOLOGY, 2023, 24 (04): : E145 - E145
12345